Category Archives: Stell Cell Research


Microscopy Devices Market: Rise in Technological Advancement Leading to Increased Consumption of Microscopy Devices – BioSpace

The global microscopy devices market is anticipated to rise in the coming years due to technological advancement and increasing number of innovations. The companies are majorly focusing on research and development to produce advanced microscopes. Biotechnology and pharmaceutical companies are engaging in these developments. Rise in engineering sector and biomedical research is also supplementing innovation of products technologies used in the market. Localization microscopy is one of the new product innovation designed by a scientist in Delft University of Technology. This new localized microscopy technique is capable to producing more and better informative images of various cellular functions including internal images of cells.

These innovations are boosting the growth of market. According to a report by Transparency Market Research, the global microscopy devices market is expected to rise at a healthy CAGR of 8.0% during the forecast period of 2017 to 2025. The global market was worth US$6,218.0 mn during 2018 and is expected to attain a valuation of US$12,351.4 mn by the end of 2025.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=226

Rigaku Corporation, X-ray analytical instrument manufacturer has highlighted its CT and XRM equipment in the Microscopy & Microanalysis 2018 meeting held in Baltimore Convention Centre, Baltimore. These new equipment enables nondestructive analysis at high resolutions of large samples. This X-ray microscopy is applicable to a wide range of materials from substances that are of low density such as biological samples to high density substances such as steels and ceramics.

Key Players Expanding Geographical Base to Fulfill Increasing Demand for Microscopy Devices

The key strategy of major players in the market are to upgrade innovations in technologies and products of microscopy devices. Various new products have successfully created high demand and set benchmark for the same. The various key companies operating in the global microscopy market are Nikon Corporation, Carl Zeiss Microscopy GmbH, Hitachi High Technologies, and Olympus Corporation. These companies are engaging in product offerings so as to increase the geographical reach and increase their customer base. These reasons are likely to garner the shares in the market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=226

Companies Launching New Techniques to Replace Conventional Ones

Olympus Corporation in 2016 had introduced a new confocal laser scanning microscope named FLUOVIEW FV300 which helped researchers in various fields such as stem cell research, cancer research, and cell biology. Nikon Corporation in 2016 also launched a new inverted microscope named ECLIPSE Ti2, which helped in providing improved usability and stability in various research applications.

Request for Discount on this Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=226

North America Consuming Major Shares Owing to Established Players in this Region

The key players are enhancing and retaining their shares in the global microscopy devices market by investing in developing cutting edge technologies that promote product uptake and offers credibility. According to a report by Transparency Market Research, Olympus Corporation in 2017 spent US$706 mn in research and development alone. Established players are creating strong presence in the market by doing the same. These global players are operating in various regions of the world. Among which, North America is consuming the highest shares in the market. Asia pacific is also witnessing rise in the growth due to implementation of industrial policies in this region that is favoring the key players in health and science areas. These factors are backed up with various government programmers and non-reimbursable funds.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Visit link:
Microscopy Devices Market: Rise in Technological Advancement Leading to Increased Consumption of Microscopy Devices - BioSpace

Researcher Calls on Others Worldwide to Join Efforts to Understand Role of Sleep in Pediatric Cancer – Rutgers-Camden NewsNow

By Tom McLaughlin

Lauren Daniel recalls that, as a clinical psychologist working with pediatric cancer patients at the Childrens Hospital of Philadelphia (CHOP), she would often arrive in the mornings to do therapy sessions and find that her patients were still sleeping.

It was then difficult for her to sit down with them, she remembers, but the predicament was understandable, since they were frequently woken up throughout the night for a variety of reasons, including vital checks, to urinate, and to get pumps and other medical equipment serviced.

For someone to wake them up during the day, it was torture for them, says the assistant professor of psychology at Rutgers UniversityCamden. They dont want to talk to you at that point.

Daniels understanding and concern would spark a career research interest in the sleep patterns of children with cancer and the connection to patients psychosocial health outcomes.

The RutgersCamden researcher is now leading an international team of sleep researchers to establish research priorities for better understanding the role of sleep in pediatric cancer. The team calls on other researchers to join them in their collaborative efforts in their paper, A call to action for expanded sleep research in pediatric oncology: A position paper on behalf of the International Psycho-Oncology Society Pediatrics Special Interest Group, in the journal Psycho-Oncology.

We are excited to put the call out there, says Daniel, who notes that three of the participating researchers spoke at the 2019 International Psycho-Oncology Society World Congress.

Daniel explains that the pediatric cancer population is thankfully small at any one center, so it is incredibly valuable for researchers to collaborate in pooling data across multiple centers.

The RutgersCamden researcher notes that research on adult cancer patients shows a bidirectional relationship linking negative health outcomes with disrupted sleep and circadian rhythms, as well as compelling evidence showing that improved sleep improves health outcomes in adults. However, she says, little is known about these effects on pediatric cancer patients.

It is essential to increase our understanding because sleep and circadian rhythms are vital components of health and quality of life, write the researchers in their paper. In children without cancer, sleep and circadian disturbances respond well to intervention, suggesting that they may also be modifiable in children with cancer.

In addition to Daniels work with the research group, she recently received a $50,000 grant from the New Jersey Commission on Cancer Research to lead the pilot program Disrupted Sleep and its Association with Symptom Burden and Reduced Engagement in Supportive Care in Pediatric Stem Cell Transplant Patients.

Daniel will work with medical professionals and psychologists on the study at CHOP to collect data on an intervention to improve sleep in pediatric cancer patients undergoing stem cell transplants.

Lauren Daniel

I am grateful for the opportunity to branch out into a new area of research and continue the work that we are doing for patients at CHOP, says Daniel.

The researchers are currently studying how sleep affects the day-to-day symptoms and coping abilities of patients in the peritransplant period, the early stage when cells are starting to graft and grow. The researchers ultimately hope to determine what they can alter to improve sleep patterns of patients and encourage changes in nursing practices accordingly in order to improve psychosocial outcomes.

Even if we can make modest gains, we hope to improve the psychosocial health outcomes in addition to medical outcomes for patients, says Daniel, who adds that there isnt a lot of psychosocial research on these patients, in part because these children are already going through intensive research.

Daniel notes an earlier study found that patients need to be woken up an average of 12 times per night.

In their forthcoming study, says the RutgersCamden researcher, pediatric patients will wear a wristwatch to measure their motion for a two-week period after receiving transplant cells and be asked to complete daily surveys on what their sleep experience was like the night before. Their symptoms, such as nausea, fatigue, anxiety, and depression, will then be assessed every five days. Researchers will also extend the intervals between vital checks and determine the effects on their symptoms.

Link:
Researcher Calls on Others Worldwide to Join Efforts to Understand Role of Sleep in Pediatric Cancer - Rutgers-Camden NewsNow

Second person ever to be cleared of HIV reveals identity – The Guardian

The second person ever to be cleared of HIV has revealed his identity, saying he wants to be an ambassador of hope to others with the condition.

Adam Castillejo, the so-called London patient, was declared free of HIV last year, 18 months after stopping antiretroviral therapy following a stem cell or bone marrow transplant to treat blood cancer.

Castillejo, 40, went public on Monday in an interview with the New York Times and revealed he had been living with HIV since 2003.

In 2012 he was diagnosed with acute myelogenous leukaemia and subsequently underwent a stem cell transplant. Crucially, the medical team picked a donor whose stem cells had two copies of a mutation that meant the white blood cells they developed into were resistant to HIV.

Timothy Brown, known as the Berlin patient and the first person to be cleared of the virus, underwent a similar treatment. However, while Brown and Castillejo had chemotherapy, only Brown had radiotherapy as part of his cancer treatment.

Last year it emerged the procedure had not only successfully treated the cancer, but that Castillejo was in remission for HIV as well. However, he chose to remain anonymous at the time.

I was watching TV and its like, OK, theyre talking about me, he told the New York Times. It was very strange, a very weird place to be.

Now Castillejo has decided to reveal his identity because he wants his case to be a cause for optimism. This is a unique position to be in, a unique and very humbling position, Castillejo said. I want to be an ambassador of hope.

Stem cell transplants are not suitable for most people with HIV because they involve a serious and invasive procedure that carries risks.

However, drug advances mean people who are HIV positive can take a pill every day to reduce their levels of the virus, preventing transmission and helping them to live a long and active life.

Prof Ravindra Gupta, the first author of the new study from Cambridge University, said Castillejos case was important: It is a second case of cure,. It means the first one wasnt an anomaly or a fluke.

See the rest here:
Second person ever to be cleared of HIV reveals identity - The Guardian

March 9, 2020 Global Stem Cell Therapy Market Set To Cross USD 4759.27 Million By 2024 – Galus Australis

Latest Report Available at Zion Market Research, Global Stem Cell Therapy Market Set For Rapid Growth, To Reach Around USD 4759.27 Million By 2024provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth. The globalStem Cell Therapy Marketresearch report is intended to help newbies as well as established market players to study and forecast this market at the global as well as regional level.Numerous important players are ruling the global market by holding a huge share of the global Stem Cell Therapy Market.

FREE | Request Sample is AvailableStem Cell Therapy Market Report @https://www.zionmarketresearch.com/sample/stem-cell-therapy-market

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Some of the Major Stem Cell Therapy Market Players Are:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

The data demonstrated in the report presents potential opportunities in the global Stem Cell Therapy Market. This assists users to make tactical moves, which lead to prospering their businesses. The report emphasizes the effect of a number of factors that can result in propelling or hindering the global as well as local Stem Cell Therapy Market. The latest research report offers the synopsis of important players who dominate the market. It includes numerous aspects such as their financial review, business strategies, as well as the latest developments in these companies.

The global Stem Cell Therapy Market research report presents a comprehensive market analysis including present market size, development rate, and value chain analysis. The segmentation of the global Stem Cell Therapy Market is done on a regional basis as well. To present a wide-ranging and competitive view of the global market, the report uses numerous methodological techniques including Porters Five Forces analysis.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

Promising Regions & Countries Mentioned In The Stem Cell Therapy Market Report:

This research report analyses various segments product, its end-users, applications, and others of the market; additionally of the global Stem Cell Therapy Market. This segmentation is done on the basis of the current as well as potential inclinations in the global Stem Cell Therapy Market. The regional segmentation of the Stem Cell Therapy Market involves the current market situation in the region along with its potential projection. The global Stem Cell Therapy Market report presents a summary of anticipated market situations owing to changes in the topographical, technological, as well as economic elements.

Browse Press Release:https://www.zionmarketresearch.com/news/stem-cell-therapy-market

Total Chapters in Stem Cell Therapy Market Report are:

Chapter 1Overview of Stem Cell Therapy Market

Chapter 2Global Market Status and Forecast by Regions

Chapter 3Global Market Status and Forecast by Types

Chapter 4Global Market Status and Forecast by Downstream Industry

Chapter 5North America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 6Europe Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 7Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 8Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 9Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 10Market Driving Factor Analysis of Low End Servers

Chapter 11Stem Cell Therapy Market Competition Status by Major Manufacturers

Chapter 12Stem Cell Therapy Market Major Manufacturers Introduction and Market Data

Chapter 13Upstream and Downstream Market Analysis of Stem Cell Therapy Market

Chapter 14Cost and Gross Margin Analysis of Stem Cell Therapy Market

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/stem-cell-therapy-market

Reason to Buy

The study objectives are:

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

More here:
March 9, 2020 Global Stem Cell Therapy Market Set To Cross USD 4759.27 Million By 2024 - Galus Australis

How wounded plants heal, survive – The Hindu

Its hard life being a plant! From pathogens and herbivores to unfavourable weather, they are constantly injured or wounded and their sessile lifestyle only adds to the trouble. Despite all this, they heal and survive. How did they evolve such a great repair mechanism? What are the molecules and proteins aiding it? These were some of the questions an international team of researchers set out to answer and have now found some interesting mechanisms.

A paper recently published in Development shows that a protein named PLETHORA (PLT), which encodes stem cell promoting factors, helps in the regeneration of the vascular system at the site of injury. This protein binds to and activates the expression of another gene (CUC2). These two together increase the production of a plant growth hormone called auxin at the wound site. The combination of these proteins and hormones gives the plant the ability to repair wounds.

The corresponding author of the paper Kalika Prasad explains that the work spanned nearly a decade to create the right set of injuries mimicking those that plants encounter throughout their life and then hunt for the plant proteins that help in this essential quick fix. He is from the School of Biology at the Indian Institute of Science Education and Research at Thiruvananthapuram (IISER-Tvm).

Though it was known that plants communicate within their different parts and with other plants during injury, not much was known about how they handle the injury. Though we carried out the initial studies on the roadside mustard plant, we noticed similar results when tested the using rice PLT protein too, he adds.

It was seen that the injury healed not just at the surface but the veins regenerated too. There was proliferation of the epithelial cells to seal the wounds and also functional restoration of tissue cells. The vein regeneration is very essential as transport of food, hormone, water, happens through it and any disruption may further hinder the plant growth, explains Dhanya Radhakrishnan, PhD scholar and first author of the paper from IISER-Tvm.

Another interesting find was that these two proteins did not play any role in the general development of vascular system but stepped into action only during its injury.

We were able to set up a mathematical model that gave us guidance that as the size of the wound changes the nature of the repair changes. The numerical simulations showed that after a particular size injury, the plant will be unable to regenerate or heal, adds Anil Shaji from the Department of Physics at IISER-Tvm. He is one of the authors of the papers and has set out to uncover the physical processes like the flow of hormones that are involved in this healing process.

We are now trying to find out all the different genes and pathways involved in the healing process and also the cellular reprogramming events. To decode if the daynight conditions affect this process would also be interesting, adds Anju P.S., a research scholar and one of the first authors of the paper from the institute. The researchers hope that in the future these genes can be produced in surplus to create plants that can withstand insect attack and other injuries.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Continue reading here:
How wounded plants heal, survive - The Hindu

Israeli Women Are Ahead In Biotech, But Don’t Have The Leadership Roles Just Yet | Health News – NoCamels – Israeli Innovation News

NoCamels Hezekiah Bird, Shuli Finley, Katie Hemmons, and Shana Jacobson contributed to this report.

Women make up 60-70 percent of roles in the biotechnology sector in Israel, a number that has not changed in almost a decade, according to the Nisha group, an Israeli recruitment and placement firm that specializes in biotech, biomed, fintech, and cleantech. But while women are ahead in the field, leading research teams and heading clinical trials, men still dominate upper management and executive roles, Nisha noted in a comprehensive report focused on women in biotech that was first published in 2012.

On Sunday International Womens Day 2020 Lizi Shoov London, Nishas partner and managing director of the companys Biotech division, confirmed to NoCamels that the numbers have not changed.

SEE ALSO: Whats The Best Advice You Got? 5 Questions With 10 Israeli Women Innovators.

Professor Rivka Carmi, former president of the Ben-Gurion University of the Negev the first and only woman to hold this position at a university says that despite the expectations that the field would mature and more women would take on executive roles, this hasnt been the case yet.

There are a lot of female researchers involved in biotech companies, she tells NoCamels, but there are not enough women in leadership roles or who have their own startups. In a time where high-tech and biotech go hand in hand, Carmi says, women only make up a third of the pie, not 50/50. The latest High-Tech Human Capital Report 2019 published by Start-Up Nation Central and the Israel Innovation Authority last month showed that the rate of women employed in the sector is at a standstill at about 30 percent, with just 22 percent for technology positions and 18 percent for tech management roles.

Carmi, who made it her mission during her 12 years as BGU president to increase cooperation between academia and industry she called it applied research set out to work with government authorities to push major biotech initiatives that would potentially make the future of women as biotech leaders a reality. These initiatives included the National Institute For Biotechnology In The Negev (NIBN), established as a company in November 2009 through a trilateral agreement between the Israeli government, founder Dr. Edgar de Picciotto, and Ben-Gurion University of the Negev, to become the first independent research entity established under the auspices of a university in Israel.

While she didnt specifically do so to put women in executive biotech positions, this was very unusual at the time, she says of NIBNs mission to bridge the gap between basic and applied research, while figuring out how to go about commercializing novel ideas and technologies developed by NIBN researchers.

I see how difficult it is for women to get leadership roles, so I am very vocal about it, she says. Women are in the minority in terms of having their own biotech startups. Many of them have to balance career and family. Not many of them want to make that concession. Its a lot of work building a startup and attracting investors.

Every woman will tell you that she encounters obstacles, Professor Carmi tells NoCamels.

Israels biotechnology and life sciences industry is a fast-growing sector, with at least 1,600 companies, including nearly 1,400 companies that were established since 2009 (thats 139 companies every year), according to the 2019 Israeli Life Sciences Report from the Israel Advanced Technology Industries (IATI.) The sector, which employs 83,000 people across the country, according to the report, has seen upwards of $1.5 billion from investors.

Even so, Dr. Irit Yaniv says that the Israeli biotech sector is enriched with but not yet dominated by women.

Dr. Yaniv is a less typical example, as she calls herself. The accomplished medtech and biopharma executive is a co-founder and investor now serving as a managing partner for health care venture capital fund Accelmed Ventures II. Dr. Yaniv has held top-level positions as CEO of heart medical device firm Impulse Dynamics and Type 2 diabetes treatment firm Metacure and a number of chairperson and board member positions at various medtech, biotech, and life science companies. She also co-founded Type 2 diabetes firm Digma Medical and obesity treatment firm NitiNotes Surgical.

But she also knows firsthand the obstacles women run into in the biotech industry. We do see many women holding mid-level positions, however when it comes to C-level (specifically, CEOs and chairperson positions), the picture is not much different from other sectors, she says.

And there is so much room for improvement. Women are still lacking the extensive networking ties and some assistance from our peers, she tells NoCamels. Women, especially younger women, are keen for proper mentoring to assist them to grow and stay at the top. I believe developing the right networks as well as other soft skills, will make a difference in the long run.

Realizing the need for mentorship and a support network for both newbies and veterans in the industry, Dr. Yaniv co-established a forum called Life Science Women. The open forum, which got too big for WhatsApp and is now on Telegram and LinkedIn, aims to establish a womens network for professional topics in the life sciences space, including HR, content, questions, lectures, and education.

The forum currently includes 300 women who use it on a daily basis, Dr. Yaniv says, with questions such as Who is willing to give a presentation at a conference? or Who knows a great service provider for regulatory matters?

Dr. Yaniv also believes another gap that prevents women from reaching high-level positions is the dissonance between how women perceive themselves and their real competencies and capabilities. For that reason, Dr. Yaniv, together with Ronit Harpaz, co-founder and CEO of medical device company Endoron Medical, and the support of the 8400 The Health Network, with a mission to advance the healthcare and life science industry in Israel, will be establishing an academic organization for junior women who have been recognized as having the potential to reach key managerial positions in their organizations. The academy will focus on teaching soft skills, networking, and specific theoretical content. It will also feature inspirational talks from prominent role models and theory segments from professional speakers.

Working together with the talented women that made it to the top, I believe we can make the change and, in the future, see more women in C-positions, including directors, she says. My wish is that there will be no need for specific women guidelines for places like board of directors, as there will be enough women holding senior positions everywhere.

SEE ALSO: Annual Biotech Confab Highlights Role of Advanced Tech Rehabilitation

Professor Carmi and Dr. Yaniv are just a few of the Israeli women who have made great strides for women in biotechnology. As the world marked International Womens Day 2020 on Sunday, NoCamels wanted to highlight the women who are making an impact in the field.

Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion Israel Institute of Technology, is one of the worlds leading scientists in the field of tissue engineering. As the head of the 3D Bio-Printing Center for Cell and Biomaterials Printing, launched last year, Levenberg is poised to lead the Technions tissue engineering into new territory. Professor Levenbergs stem cell and tissue engineering research has shown that it is possible to generate tissues and blood vessels in a lab that can in the future be implanted and integrated into human hosts.

Professor Levenberg is also the co-founder and Chief Scientific Officer of Aleph Farms, a clean meat Israeli company that unveiled the worlds first lab-grown steak prototype grown from animal cells in Dec 2018. Founded in 2017, Aleph Farms has raised more than $14 million and is working to transform its prototype into a commercial product.

Professor Levenberg has co-authored more than 100 publications, including six in 2019. In 2007, she appeared on Scientific Americans list of 50 leading scientists, Last year, she was named one of 50 influential women in 2019 by Israeli magazine Lady Globes.

Dr. Ora Dar has almost three decades of science, tech, and management experience, including 13 years as the head of the life sciences sector at the Israel Innovation Authority (then the Office of the Chief Scientist.) She also spent 16 years on academic research and has been a venture capital consultant for over two decades.

Today, Dr. Dar leads the National Infrastructure Forum for Research and Development (Telem) at the Israel Innovation Authority. She is also among the leaders of the Israeli National Genomic and Personalized Medicine Initiative, which includes a research-oriented genomic-clinical database of 100K volunteers.

Dr. Dar co-chairs the annual MIXiii-BIOMED Conference and Exhibition, a leading biotechnology and healthcare conference for both Israeli and international professionals.

Dr. Nuha Higazi, a neurology doctor, is the CTO and co-founder of PamBio, a biotechnology company developing drug therapy for hemorrhagic stroke (intracranial bleeding and ICH) and other acute bleeding conditions.

The company, co-founded with her husband Professor Abd Higazi with the support of Hadassah Medical Centers technology transfer company Hadasit, was conceived as part of the Nazareth-based incubator (NGT)3 and has received $7 million in a Series A round and $3 million from both (NGT)3 and the Israel Innovation Authority since it was founded in 2014.

Dr. Higazi is also the CTO and co-founder of medical device company Plas-free, which has developed ClearPlasma, a medical device that helps coagulation and complex treatments for massive bleeding. The company was founded in 2017.

Professor Mouna Maroun researches PTSD on animal models while focusing on developmental differences at the Univerity of Haifas Sagol Department of Neurobiology. She heads the Universitys Laboratory for Neurobiology of Emotions.

In 2018, Professor Maroun was named by the business publication TheMarker as one of the top 20 women changing the face of the Israeli medical scene today.

As an Arab woman, my belief is that the revolution towards gender and ethnic equality starts top-down at academic institutions, she told the University of Haifa magazine in 2018. Recruiting outstanding women as faculty members Jewish, Arab, Ethiopian and Haredi especially in sciences and STEM [Science, Technology, Engineering and Mathematics] subjects is one of the first steps to ensure the representation of women in higher education and to convey a clear message to the younger generation that there is no glass ceiling for girls.

Since joining genomics-based cancer immunotherapy and diagnostic discovery company Compugen in 2002, Dr. Anat Cohen-Dayag has held numerous positions including vice president of R&D as she climbed up the ladder. In 2010, Dr. Cohen-Dayag was named Compugens president and CEO and has been on the companys board of directors since 2014.

Last month, Compugen announced the expansion of its cooperation agreement with international firm Bristol-Myers Squibb to conduct cancer treatment trials. This week, the company reported promising data from on ongoing Phase 1 trial of its lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors.

Dr. Cohen-Dayag is also the director of the Israel Advanced Technology Industry (IATI), Israels umbrella organization of high-tech and life science industries, heading up more than 700 members from every level and aspect of the ecosystem including venture capital funds, R&D centers, and startup incubators.

Another biotech force is Dr. Kinneret Livnat-Savitzky, the CEO of Israeli biotechnology accelerator FutuRx Ltd established in 2014. She joined Compugens board of directors in 2018.

She previously completed a seven-year stint as CEO of clinical-stage, publicly-traded biopharma company BioLineRX, which focuses on oncology, as well as seven years as VP of biology at Compugen.

Professor Ester Segal is currently leading a research group focusing on the broad interface between materials science and biotechnology in the Faculty of Biotechnology and Food Engineering at the Technion Israel Institute of Technology. She is also head of the Esther Segal lab at the Technion, which implements a multidisciplinary approach that couples materials science with engineering, and chemistry with biotechnology to address problems in biotechnology, food engineering, and medicine.

Professor Segal is a recipient of the 2019 Advances in Measurement Science Lectureship Award for her work on photonic crystal sensing.

Last year, she was named among the top 50 most influential women in Israel in 2019 by Lady Globes magazine.

Nora Nseir is the co-founder and CTO of Nurami Medical, a medical device company with a breakthrough nanofiber and sealant technology for the soft tissue repair market. Nseir, a biomedical engineer co-founded the startup in 2014 with Dr. Amir Bahar, a multidisciplinary entrepreneur and neuroscientist. Nseir previously held R&D positions in the medical devices industry focusing on the development of bone grafts and hemostatic devices.

In 2015, she co-founded the Arab Women in Science forum, which encourages Arab women and girls in sciences and entrepreneurship.

In 2017 and 2018, Nseir was also included in the Lady Globes Women of Influence list.

Go here to see the original:
Israeli Women Are Ahead In Biotech, But Don't Have The Leadership Roles Just Yet | Health News - NoCamels - Israeli Innovation News

GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in…

DRESDEN, Germany, March 9, 2020 /PRNewswire/ --GEMoaB, a biopharmaceutical company focused on the development of next generation immunotherapies for hard-to-treat cancers, today announced that it has apheresed the first patient in a Phase IA study with UniCAR-T-CD123, the lead product candidate from its proprietary UniCAR cellular immunotherapy platform. UniCAR has been designed to ensure excellent control over the universal CAR-T effector cell through a rapidly switchable on/off capability. This is combined with high flexibility to effectively target tumor antigens of choice by re-directing and activating CAR-T effector cells through soluble adapters termed Targeting Modules (TMs). UniCAR-T-CD123 is investigated in late stage, relapsed/refractory Acute Leukemias expressing the CD123 antigen.

The Phase IA study includes patients with CD123 positive relapsed/refractory Acute Myeloid Leukemia (AML) post standard treatment as well as CD123 positive relapsed/refractory Acute Lymphoblastic Leukemia (ALL) post CD19-targeting therapies and will examine the feasibility, safety and potential efficacy of the combined application of a single dose of UniCAR-T and the continuous infusion of the CD123 specific Targeting Module TM123.

"The ability to rapidly switch on and off the CAR-T effector cells of our UniCAR platform and thereby tightly control their activity may help to overcome many of the limitations that current CAR-T therapies face, especially when targeting less differentially expressed antigens and solid tumors," said Prof. Dr. Gerhard Ehninger, GEMoaB's co-founder and Chief Medical Officer. "The start of the first UniCAR clinical studythereforeis not only an important milestone for our company but could also lead to an important advancement in cellular immunotherapy beyond targeting CD19 and BCMA."

According to Prof. Bob Lwenberg, Department of Hematology at Erasmus University Medical Center Rotterdam, The Netherlands, the study could be an important step in the research efforts to improve patient outcomes in relapsed/refractory Acute Leukemias, which belong to the most difficult to treat blood cancers. "Despite recent advances, patients with acute leukemia who progress after currently available treatment approaches, generally have a notoriously poor prognosis with only very limited options. This trial will contribute to the development of a safe and effective cellular immunotherapy against the validated target antigen CD123 in these deadly diseases and potentially offer an alternative to allogeneic hematopoietic stem cell transplants in the future."

About the UniCAR-T-CD123 Study

This first-in-human phase I study is an open-label, non-randomized, dose-finding study designed to evaluate the safety and activity of UniCAR-T-CD123 in up to 16 CD123 positive patients with relapsed/refractory Acute Leukemias. Its purpose is to determine the maximum tolerated dose (MTD) as well as Dose limiting toxicities (DLT) of the combined application of a single dose of UniCAR-T and the continuous infusion of TM123 over 25 days. Application will follow post salvage therapy and lymphodepletion. The study will also investigate persistence of UniCAR-T cells over time as well as the ability to rapidly switch UniCAR-T cells on and off in case of side effects through stopping TM infusion. The study will take place at selected Phase I, Acute Leukemia and CAR-T experienced University centers in Germany. The study is jointly conducted with Cellex Patient Treatment and supported by a grant from the German Federal Ministry for Education and Research (project "TurbiCAR"). To learn more about the trial, please visit clinicaltrials.gov.

About UniCAR

GEMoaB is developing a rapidly switchable universal CAR-T platform, UniCAR, to improve the therapeutic window and increase efficacy and safety of CAR-T cell therapies in more challenging cancers, including solid tumors. Standard CAR-T cells depend on the presence and direct binding of cancer antigens for activation and proliferation. An inherent key feature of the UniCAR platform is a rapidly switchable on/off mechanism (less than 4 hours after interruption of TM supply) enabled by the short pharmacokinetic half-life and fast internalization of soluble adaptors termed targeting modules (TMs). These TMs provide the antigen-specificity to activate UniCAR gene-modified T-cells (UniCAR-T) and consist of a highly flexible antigen-binding moiety, linked to a small peptide motif recognized by UniCAR-T.

AboutGEMoaB

GEMoaB is a privately-owned, clinical-stage biopharmaceutical company that isaiming to become a globally leading biopharmaceutical company. By advancing its proprietary UniCAR, RevCAR and ATAC platforms, the company will discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients with a high unmet medical need.

GEMoaB has a broad pipeline of product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors. Its clinical stage assets GEM333, an Affinity-Tailored Adaptor for T-Cells (ATAC) with binding specificity to CD33 in relapsed/refractory AML, and GEM3PSCA, an ATAC with binding specificity to PSCA for the treatment of castrate-resistant metastatic prostate cancer and other PSCA expressing late stage solid tumors, are currently investigated in Phase I studies and globally partnered with Bristol-Myers Squibb/Celgene. A Phase IA dose-finding study of the first UniCAR asset, UniCAR-T-CD123 for treatment of relapsed/refractory AML and ALL has been initiated, UniCAR-T-PSMA against CRPC and other PSMA-expressing late-stage solid tumors, is planned to be tested in a Phase I study initiated by H2 2020.

Manufacturing expertise, capability and capacity are key for developing cellular immunotherapies for cancer patients. GEMoaB has established a preferred partnership with its sister company Cellex in Cologne, a world leader in manufacturing hematopoietic blood stem cell products and a leading European CMO for CAR-T cells, co-operating in that area with several large biotech companies.

Forward-looking Statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results and matters discussed in the forward looking statements. Forward looking statements include statements concerning our plans, goals, future events and or other information that is not historical information.

The Company does not assume any liability whatsoever for forward-looking statements. The Company assumes that potential partners will perform and rely on their own independent analyses as the case may be. The Company will be under no obligation to update the Information.

More information can be found at http://www.gemoab.com.

For further information please contact:Constanze Medackc.medack@gemoab.com; Tel.: +49-351-4466-45027

Investor ContactMichael Pehlm.pehl@gemoab.com; Tel.: +49-351-4466-45030

View original content to download multimedia:http://www.prnewswire.com/news-releases/gemoab-announces-first-patient-apheresed-in-a-phase-ia-study-with-lead-product-candidate-from-rapidly-switchable-universal-car-t-platform-unicar-in-cd123-positive-relapsedrefractory-acute-leukemias-301019785.html

SOURCE GEMoaB

Here is the original post:
GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in...

Complete growth overview on Cryopreservation Equipment in Stem Cells Market in 2020-2025 including top key players Thermo Fisher Scientific, Charter…

Cryopreservation Equipment in Stem Cells Market Insights 2020, is a professional and in-depth study on the current state of the global Cryopreservation Equipment in Stem Cells Industry with a focus on the global market. An elaborate and comprehensive primary analysis report highlights numerous facets such as business enhancement strategies, development factors, financial gain, statistical growth or loss to help readers and clients understand the market on a global scale.

Prominent key players operating in the Global Cryopreservation Equipment in Stem Cells Market: Thermo Fisher Scientific, Charter Medicals, Linde Gas Cryoservices, praxair

The market has witnessed rapid development in the past and present years and is likely to expand in the near future. In the market report, there is a segment for the competitive landscape of the key players operating in the global industry. Overall, the report provides an in-depth insight into the 2020-2025 global Cryopreservation Equipment in Stem Cells market encompassing all important parameters.

Click Here To Access The Sample Report: https://www.acquiremarketresearch.com/sample-request/333642/

Cryopreservation Equipment in Stem Cells Market Statistics by Types: Liquid Phase, Vapor Phase

Cryopreservation Equipment in Stem Cells Market Outlook by Applications: Totipotent Stem Cell, Pluripotent Stem Cell

The report is a professional, all-inclusive study on the present state of the Cryopreservation Equipment in Stem Cells industry with a focus on the global market. Through the statistical analysis, the report depicts the global total market of the Cryopreservation Equipment in Stem Cells Element industry including capacity, production, production value, cost/profit, supply/demand, and Chinese import/export. In general, the study presents a detailed overview of the worldwide market covering all major parameters.

To Get This Report At Beneficial Rates: https://www.acquiremarketresearch.com/discount-request/333642/

Owning our reports will help you solve the following issues:

1. Uncertainty about the future? Our research and insights help our clients to foresee upcoming revenue pockets and growth areas. This helps our clients to invest or divest their resources.2. Understanding market sentiments? It is imperative to have a fair understanding of market sentiments for a strategy. Our insights furnish you with a hawk-eye view on market sentiment. We keep this observation by engaging with Key Opinion Leaders of a value chain of each industry we track.3. Understanding the most reliable investment centers? Our research ranks investment centers of the market by considering their returns, future demands, and profit margins. Our clients can focus on the most prominent investment centers by procuring our market research.4. Evaluating potential business partners? Our research and insights help our clients in identifying compatible business partners.

Cryopreservation Equipment in Stem Cells Market by Region Segmentation: North America Country (United States, Canada)Asia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Key Points Describing Various Features of Report:-

Manufacturing Analysis The Cryopreservation Equipment in Stem Cells market includes a section featuring manufacturing process investigation approved by means of essential data collated through Industry specialists and Key authorities of profiled organizations.

Cryopreservation Equipment in Stem Cells Market Competition Leading professionals have been investigated depending on their company profile, product database, capacity, product/service value, transactions, and cost/revenue.

Demand & Supply and Effectiveness Furthermore, The Cryopreservation Equipment in Stem Cells report provides information on distribution, Production, Consumption & EXIM (Export & Import).

Interested in purchasing this Report? Click here @ https://www.acquiremarketresearch.com/buy-now/333642/?price=su

Request a customized copy of Cryopreservation Equipment in Stem Cells reportIf you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will customize the report as you want.

Finally, the Cryopreservation Equipment in Stem Cells Market report is an authentic source for gaining the market research that is likely to exponentially accelerate your business. The report gives the principle locale, economic situations coupled with item value, benefit, limit, generation, supply, request, and market development rate and figure and so on. The Cryopreservation Equipment in Stem Cells reports additionally presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Go here to read the rest:
Complete growth overview on Cryopreservation Equipment in Stem Cells Market in 2020-2025 including top key players Thermo Fisher Scientific, Charter...

Cell Separation Technologies Market 2020 Analysis Research and Trends Report for 2026 – Galus Australis

Cell Separation Technologies Market

The Cell Separation Technologies Market report is a valuable source of insightful data for business strategists. The report also helps in understanding the global Cell Separation Technologies market through key segments including application, product type, and end user. This analysis is based on various parameters such as CGAR, share, size, production, and consumption. This helps the competitors in taking well-versed business decisions by having overall insights of the market scenario. Report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries.

The globalmarketforcell separation technologies predicted to cross $6.2 billion by 2026, expanding at a CAGR of 10.0% over the forecast 2020-2026

Cell separation technologies involve the separation of cells from a heterogeneous cell mixture according to their intracellular or extracellular properties. Cell separation has gained importance in the fields of medicine and biology as it is an essential component of cellular therapy and disease diagnosis. The recent expansion of the field of cell separation is linked to an increase the mortality rate due to chronic diseases as majority of these diseases can be treated using cell-based therapies.

The report has also focused on the competitive landscape and the key strategies deployed by the market participants to strengthen their presence in the global Cell Separation Technologies market. Leading players operating in the global Cell Separation Technologies market comprising Mitenyi Biotec GmbH, BD Bioscience, STEMCELL Technologies Terumo BCT, pluriSelect GmbH, EMD Millipore, Life Technologies, also profiled in the report.

Get Sample PDF Copy of This Report (Up to30% Discount)https://www.marketinsightsreports.com/reports/03091886414/global-cell-separation-technologies-market-size-status-and-forecast-2020-2026/inquiry?Mode=31

The Global Cell Separation Technologies market elaborate report, offers a summary study on regional forecast, business size, and associated revenue estimations. The Cell Separation Technologies report more emphasizes primary challenges and growth trends adopted by leading makers of the market.

This report segments the global Cell Separation Technologies Market on the basis of Types areGradient CentrifugationSurface Markers SeparationFluorescence Activated Cell SortingMagnetic Cell SortingOthers

On The basis Of Application, the Global Cell Separation Technologies Market is

Oncology ResearchNeuroscience ResearchStem Cell ResearchMicrobiology and Immunology ResearchOthers

Inquire for Discounthttps://www.marketinsightsreports.com/reports/03091886414/global-cell-separation-technologies-market-size-status-and-forecast-2020-2026/discount?Mode=31

Regional Analysis:

The report provides a detailed breakdown of the market region-wise and categorizes it at various levels. Regional segment analysis displaying regional production volume, consumption volume, revenue, and growth rate from 2020-2026 covers: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Through the measurable examination, the report delineates the universal Cell Separation Technologies Market including limit, generation, creation esteem, cost/benefit, supply/request and worldwide import/send out. The all out market is additionally isolated by organization, by nation, and by application/type for the aggressive scene examination. The report at that point gauges 2020-2026 market improvement patterns of industry. Examination of upstream crude materials, downstream interest, and current market elements is additionally completed. At last, the report makes some significant proposition for another undertaking of Cell Separation Technologies Market before assessing its attainability.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/03091886414/global-cell-separation-technologies-market-size-status-and-forecast-2020-2026?Mode=31

Significant Features that are under Offering and Key Takeaways from this Report:

We Also Offer Customization on report based on specific client Requirement

Free country Level analysis for any 5 countries of your choice.Free Competitive analysis of any 5 key market players.Free 40 analyst hours to cover any other data point.

ABOUT US

Market Insights Reports is an online market research reports library of 500,000 in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact Us

Irfan Tamboli Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]/[emailprotected]

Originally posted here:
Cell Separation Technologies Market 2020 Analysis Research and Trends Report for 2026 - Galus Australis

Federal government investing nearly $7 million in stem cell research – inthehammer.com

The federal government recently announced their intention to invest $6.9 million in stemcellresearch.

Stem cells are the building blocks of the body, and are responsible for growing and repairing tissue; they have the potential to treat myriad illnesses including heart disease--the leading cause of death inNorthAmerica.

Canada has been one of the leading countries when it comes to stem cell research, and Canadian researchers have brought stem cells from the lab into hospitals to savecountlesslives.

This funding will go towards nine translational projects and four clinical trials across the country aimed at providing new therapies and fostering continued growth in Canada's regenerativemedicinesector.

Two of the projects are being conducted by the Maisonneuve-Rosemont Hospital in Quebec; one trial involves testing a promising new protocol to make blood stem cell transplants available to more patients with severe leukemia, the other is a biotechnology partnership that is advancing a stem cell-based approach tovisionloss.

"When we invest in science, we invest in better, healthier lives for everyone," Navdeep Bains, Minister of Innovation, Science, and Industry, said in anewsrelease.

"Our government's support will help Canadian researchers further their ground-breaking work to tackle some of the most serious illnesses we face today. Congratulations to all of the recipients, and thank you for your work to keep Canada on the cutting edge of discovery and innovation,"hecontinued.

Go here to read the rest:
Federal government investing nearly $7 million in stem cell research - inthehammer.com